Assessing treatment response in multiple sclerosis

Area of Science:

• Neurology
• Immunology
• Biomarker Research

Background:

• Multiple sclerosis (MS) management is evolving from a relapse-focused approach to understanding continuous inflammatory and neurodegenerative processes.
• Traditional clinical measures inadequately capture the full disease progression and long-term disability.
• Subtle clinical deterioration and insidious progression necessitate more sensitive monitoring strategies.

Purpose of the Study:

• To review the evolving landscape of multiple sclerosis (MS) treatment response evaluation.
• To highlight the limitations of traditional clinical measures in detecting disease progression.
• To emphasize the need for integrated monitoring strategies incorporating advanced assessments.

Main Methods:

• Review of current clinical assessment tools and their limitations.
• Evaluation of advanced functional assessments for enhanced sensitivity.
• Assessment of Magnetic Resonance Imaging (MRI) for detecting subclinical inflammatory activity.
• Analysis of neurodegenerative biomarkers, including optical coherence tomography (OCT) and fluid biomarkers (serum neurofilament light chain [sNfL], glial fibrillary acidic protein [GFAP]).

Main Results:

• Traditional clinical measures are insufficient for detecting subtle disease progression and long-term disability.
• Enhanced functional assessments offer greater sensitivity to clinical changes.
• MRI is crucial for identifying subclinical focal inflammatory activity.
• Biomarkers like OCT, sNfL, and GFAP provide insights into diffuse neurodegenerative processes.

Conclusions:

• A personalized monitoring strategy integrating clinical assessment, imaging, and fluid biomarkers is essential for contemporary MS care.
• This integrated approach promises improved detection of subclinical disease activity.
• It enables more accurate risk stratification and informed, individualized treatment decisions.